Mark Velleca
Chief Executive Officer at BLACK DIAMOND THERAPEUTICS, INC.
Net worth: 685 487 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Epstein | M | 65 | 10 years | |
Norman Sharpless | M | 57 | 10 years | |
Jack Bailey | M | 59 | 4 years | |
Elizabeth Buck | M | 49 | 10 years | |
Aravind Asokan | M | - |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | - |
Kristof Zsolt Szalay | M | 38 |
Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
Turbine Hálózatelemzo Kutatási Fejlesztési Kft. Packaged SoftwareTechnology Services Part of Turbine Simulated Cell Technologies Ltd., Turbine Hálózatelemzo Kutatási Fejlesztési Kft. The Hungarian company specializes in unlocking therapies with simulated cells™. Turbine computationally simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease. The simulations can reveal the right modality and combination approach to treat even the most resistant cancers. The company's platform enables the simulation of drug-like effects from compounds that may not exist yet, on cells potentially unavailable for lab-based testing, like those of high unmet need cancer patients. is a Budapest-based company founded in 2013 by Daniel Veres, Szabolcs Nagy, and Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2013. | 11 years |
Anil K. Goyal | M | 59 |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology IMMvention Therapeutix, Inc. is an American biotechnology company that develops therapies. The company was founded by Jenny Ting and the CEO is Anil K. Goyal. | - |
Szabolcs Nagy | M | 35 |
Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
Turbine Hálózatelemzo Kutatási Fejlesztési Kft. Packaged SoftwareTechnology Services Part of Turbine Simulated Cell Technologies Ltd., Turbine Hálózatelemzo Kutatási Fejlesztési Kft. The Hungarian company specializes in unlocking therapies with simulated cells™. Turbine computationally simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease. The simulations can reveal the right modality and combination approach to treat even the most resistant cancers. The company's platform enables the simulation of drug-like effects from compounds that may not exist yet, on cells potentially unavailable for lab-based testing, like those of high unmet need cancer patients. is a Budapest-based company founded in 2013 by Daniel Veres, Szabolcs Nagy, and Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2013. | 11 years |
Monica Thomas | F | - | 1 years | |
Garry Nicholson | M | 69 | 6 years | |
Lei Zhang | M | 51 |
Yale University
| - |
William C. Roberts | M | 54 | 3 years | |
Ali Behbahani | M | 47 | 6 years | |
Richard Foster | M | 82 |
Yale University
| - |
Brent Hatzis-Schoch | M | 59 | 5 years | |
Cynthia Flowers | F | 64 | 6 years | |
Kapil Dhingra | M | 64 | 3 years | |
Alicia Secor | F | 62 | 3 years | |
Radha Kuppalli | F | - |
Yale University
| 16 years |
Ari Helenius | M | - |
Yale University
| 41 years |
Garry Menzel | M | 59 | 10 years | |
Greg P. Bertenshaw | M | - |
BioMarker Strategies LLC
BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD. | 13 years |
Rosemarie Loffredo | F | - |
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | 11 years |
Daniel Veres | M | 35 |
Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
Turbine Hálózatelemzo Kutatási Fejlesztési Kft. Packaged SoftwareTechnology Services Part of Turbine Simulated Cell Technologies Ltd., Turbine Hálózatelemzo Kutatási Fejlesztési Kft. The Hungarian company specializes in unlocking therapies with simulated cells™. Turbine computationally simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease. The simulations can reveal the right modality and combination approach to treat even the most resistant cancers. The company's platform enables the simulation of drug-like effects from compounds that may not exist yet, on cells potentially unavailable for lab-based testing, like those of high unmet need cancer patients. is a Budapest-based company founded in 2013 by Daniel Veres, Szabolcs Nagy, and Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2013. | 11 years |
Erika Jones | F | 39 | 5 years | |
Samarth Kulkarni | M | 45 | 5 years | |
Richard Levin | M | 77 |
Yale University
| 31 years |
Glenn Muir | M | 65 | 9 years | |
Fang Ni | M | 37 | 4 years | |
Jacks Lee | M | 60 | 2 years | |
Terry Murdock | M | 64 | 7 years | |
Jenny Ting | M | - |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology IMMvention Therapeutix, Inc. is an American biotechnology company that develops therapies. The company was founded by Jenny Ting and the CEO is Anil K. Goyal. | - |
Martha Woodcock | F | - |
Yale University
| - |
Susan Medak | F | - |
Yale University
| - |
Melanie Ginter | F | - |
Yale University
| - |
Alexandros Makridis | M | 62 |
Yale University
| - |
Michael Warren | M | 56 |
Yale University
| - |
Malcolm Gilchrist | M | 75 |
Yale University
| - |
Christopher di Bonaventura | M | - |
Yale University
| - |
Sondra Cruver | F | - |
Yale University
| - |
Steve Blum | M | 72 |
Yale University
| - |
Sean T. Dixon | M | - |
Yale University
| - |
Joanne B. Weidhaas | M | - |
Yale University
| - |
Julie Braverman | F | - |
Yale University
| - |
Michael Northrop | M | - |
Yale University
| - |
Paul T. Anastas | M | - |
Yale University
| - |
Philip Himberg | M | - |
Yale University
| - |
Sandra A. Carson | M | 70 |
Yale University
| - |
John Puziss | M | - |
Yale University
| 23 years |
Rishay Patel | M | - |
Yale University
| 3 years |
William Sessa | M | - |
Yale University
| - |
Hyuk-Jeen Suh | M | - |
Yale University
| 4 years |
Joseph F. Renzulli | M | - |
Yale University
| - |
Denny Sakkas | M | - |
Yale University
| - |
Scott Schoen | M | 65 |
Yale University
| - |
Kyle Pruett | M | - |
Yale University
| - |
George Baker | M | 81 |
Yale University
| - |
John Deno Geanakoplos | M | 68 |
Yale University
| 38 years |
Lauren Zucker | F | 54 |
Yale University
| 13 years |
David Sze | M | 58 |
Yale University
| - |
Leon E. Rosenberg | M | 90 |
Yale University
| 25 years |
Vincent Marchesi | M | 88 |
Yale University
| 51 years |
Ernesto Zedillo Ponce de León | M | 71 |
Yale University
| 22 years |
Harvey J. Berger | M | 74 |
Yale University
| - |
Alan G. Schwartz | M | 84 |
Yale University
| 37 years |
William L. Jorgensen | M | - |
Yale University
| - |
Donald M. Engelman | M | 83 |
Yale University
| 45 years |
Howard Newman | M | 76 |
Yale University
| - |
Douglas Warner | M | 77 |
Yale University
| - |
William Miller | M | 67 |
Yale University
| - |
Elan Gandsman | M | 82 |
Yale University
| 31 years |
James Tananbaum | M | 60 |
Yale University
| - |
Tom Glocer | M | 63 |
Yale University
| - |
Harry Ballan | M | - |
Yale University
| - |
Kenneth V. Schwartz | M | - |
Yale University
| - |
Leo M. Cooney | M | - |
Yale University
| - |
Jonathan R. Macey | M | 68 |
Yale University
| - |
William Konigsberg | M | - |
Yale University
| - |
James Gustave Speth | M | - |
Yale University
| - |
David Nierenberg | M | 70 |
Yale University
| - |
Amy Wrzesniewski | M | - |
Yale University
| - |
Viswanathan Vinay | M | - |
Yale University
| - |
Frances G. Beinecke | F | - |
Yale University
| - |
Martin H. Schultz | M | - |
Yale University
| - |
Marcella Bradway | M | - |
Yale University
| - |
Alvin K. Klevorick | M | - |
Yale University
| - |
Vincent Pieribone | M | - |
Yale University
| - |
Elyse G. Seltzer | M | 59 |
Yale University
| - |
Patricia Sue Fitzsimons | M | - |
Yale University
| - |
Peter Lu | M | - |
Yale University
| - |
Kathleen Walsh | F | 68 |
Yale University
| - |
Ralph E. Grossi | M | - |
Yale University
| - |
E. Jonathan Soderstrom | M | 69 |
Yale University
| - |
Peter N. Herbert | M | - |
Yale University
| 33 years |
Stephen L. Carter | M | - |
Yale University
| - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jay C. Strum | M | - | 11 years | |
Troy Wilson | M | 55 |
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | 5 years |
Christy Shaffer | M | 66 | 6 years | |
Seth A. Rudnick | M | 75 | 7 years | |
Jennifer Moses | F | 49 | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 97 | 97.00% |
Hungary | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark Velleca
- Personal Network